MicroRNA在糖尿病性骨质疏松症中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.02.311

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (2): 311-316.doi: 10.16352/j.issn.1001-6325.2023.02.311

MicroRNA在糖尿病性骨质疏松症中作用的研究进展

杨孟迪¹, 丁雨露¹, 王玉洁¹, 何风英¹, 孙琳楠¹, 甄东户^2*

1.兰州大学第一临床医学院内分泌科, 甘肃兰州 730000;
2.兰州大学第一医院内分泌科,甘肃兰州 730000

收稿日期:2021-09-30 修回日期:2022-04-07 出版日期:2023-02-05 发布日期:2023-02-02
通讯作者: ^*zhdh8279@163.com
基金资助:
甘肃省自然科学基金(21JR1RA096);上海市医药卫生发展基金会糖尿病临床研究项目(Ⅰ期10研究);标准化代谢性疾病管理中心(MMC)专项研究基金(2018-mmczxjj-3);甘肃省内分泌疾病临床医学研究中心(20JR10FA667)

Research progress on the role of microRNA in diabetic osteoporosis

YANG Mengdi¹, DING Yulu¹, WANG Yujie¹, HE Fengying¹, SUN Linnan¹, ZHEN Donghu^2*

1. Department of Endocrinology, the First Clinical Medical College,Lanzhou University,Lanzhou 730000;
2. Department of Endocrinology,the First Hospital,Lanzhou University,Lanzhou 730000,China

Received:2021-09-30 Revised:2022-04-07 Online:2023-02-05 Published:2023-02-02
Contact: ^*zhdh8279@163.com

摘要/Abstract

摘要： 糖尿病性骨质疏松症(DOP)是糖尿病患者中常见的骨代谢性疾病。在高糖(HG)环境下,异常表达的微小RNA(miRNA)通过对Wnt/β-catenin信号通路中关键分子的调节,干扰骨髓间充质干细胞(BM-MSCs)成骨分化,导致DOP的发生发展。探索miRNA在DOP中的作用可为诊断和治疗DOP提供新的思路。

关键词: 糖尿病, 骨质疏松症, 微小RNA, Wnt信号通路, 间充质干细胞

Abstract: Diabetic osteoporosis (DOP) is a common bone metabolic disease in patients with diabetes. Under the high glucose (HG) environment, abnormally expressed microRNA (miRNA) interferes with osteogenic differentiation of bone marrow mesenchymal stem cells (BM-MSCs) by regulating key molecules in the Wnt/β-catenin signaling pathway, leading to the occurrence and development of DOP. Exploring the role of miRNA in DOP can provide new ideas for the diagnosis and treatment of DOP.

Key words: diabetes mellitus, osteoporosis, microRNAs, Wnt signaling pathway, mesenchymal stem cells

中图分类号:

R580
R587.2

杨孟迪, 丁雨露, 王玉洁, 何风英, 孙琳楠, 甄东户. MicroRNA在糖尿病性骨质疏松症中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 311-316.

YANG Mengdi, DING Yulu, WANG Yujie, HE Fengying, SUN Linnan, ZHEN Donghu. Research progress on the role of microRNA in diabetic osteoporosis[J]. Basic & Clinical Medicine, 2023, 43(2): 311-316.

参考文献 27

[1]	刘中胜, 杨建虹. 未羧化骨钙素对高糖条件下小鼠骨髓间充质干细胞成骨与成脂分化的调控效应[J]. 中国组织工程研究, 2020, 24:2039-2046.
[2]	Zhou P, Li Y, Di R, et al. H19 and Foxc2 synergistically promotes osteogenic differentiation of BMSCs via Wnt-β-catenin pathway[J]. J Cell Physiol, 2019, 234:13799-13806.
[3]	Zheng T, Ji G, Chen J, et al. MicroRNA-142 protects MC3T3-E1 cells against high glucose-induced apoptosis by targeting β-catenin[J]. Exp Ther Med, 2020, 20:125-125.
[4]	郑洁, 郭海英, 潘思京, 等. 表观遗传调控与骨质疏松症的研究进展[J]. 基础医学与临床, 2014, 34:406-409.
[5]	Tang CY, Wu M, Zhao D, et al. Runx1 is a central regulator of osteogenesis for bone homeostasis by orchestrating BMP and WNT signaling pathways[J]. PLoS Genet, 2021, 17:e1009233-e1009233.
[6]	Zhai Z, Chen W, Hu Q, et al. High glucose inhibits osteogenic differentiation of bone marrow mesenchymal stem cells via regulating miR-493-5p/ZEB2 signalling[J]. J Biochem, 2020, 167:613-621.
[7]	He C, Liu M, Ding Q, et al. Upregulated miR-9-5p inhibits osteogenic differentiation of bone marrow mesenchymal stem cells under high glucose treatment[J]. J Bone Miner Metab, 2022, 40:208-219.
[8]	曲野, 刘立柱, 徐瑞敏, 等. miR-295抑制高糖诱导的小鼠成骨细胞系MC3T3-E1的凋亡[J]. 基础医学与临床, 2021, 41:1588-1593.
[9]	Zhang ZD, Ren H, Wang WX, et al. IGF-1R/β-catenin signaling axis is involved in type 2 diabetic osteoporosis[J]. J Zhejiang Univ Sci B, 2019, 20:838-848.
[10]	Li Z, Zhao H, Chu S, et al. miR-124-3p promotes BMSC osteogenesis via suppressing the GSK-3β/β-catenin signaling pathway in diabetic osteoporosis rats[J]. In Vitro Cell Dev Biol Anim, 2020, 56:723-734.
[11]	Cao Y, Qiu Y, Liu MX, et al. miR-29c-3p reduces bone loss in rats with diabetic osteoporosis via targeted regula-tion of Dvl2 expression[J]. Eur Rev Med Pharmacol Sci, 2021, 25:636-642.
[12]	Jiang F, Zong Y, Ma X, et al. miR-26a attenuated bone-specific insulin resistance and bone quality in diabetic mice[J]. Mol Ther Nucleic Acids, 2020, 20:459-467.
[13]	Wang R, Zhang Y, Jin F, et al. High-glucose-induced miR-214-3p inhibits BMSCs osteogenic differentiation in type 1 diabetes mellitus[J]. Cell Death Discov, 2019, 5:143-143.
[14]	Amjadi-Moheb F, Akhavan-Niaki H. Wnt signaling path-way in osteoporosis: epigenetic regulation, interaction with other signaling pathways, and therapeutic promises[J]. J Cell Physiol, 2019, 234:14641-14650.
[15]	Jiating L, Buyun J, Yinchang Z. Role of metformin on osteoblast differentiation in type 2 diabetes[J]. Biomed Res Int, 2019, 2019:9203934.doi:10.1155/2019/9203934.eldlection 2019.
[16]	Wu L, Zhang G, Guo C, et al. Intracellular Ca(2+) signaling mediates IGF-1-induced osteogenic differentiation in bone marrow mesenchymal stem cells[J]. Biochem Biophys Res Commun, 2020, 527:200-206.
[17]	Gan K, Dong GH, Wang N, et al. miR-221-3p and miR-222-3p downregulation promoted osteogenic differentiation of bone marrow mesenchyme stem cells through IGF-1/ERK pathway under high glucose condition[J]. Diabetes Res Clin Pract, 2020, 167:108121.doi:10.1016/j.diabres.2020.108121.
[18]	Varma Shrivastav S, Bhardwaj A, Pathak KA, et al. Insulin-like growth factor binding protein-3 (IGFBP-3): unraveling the role in mediating IGF-independent effects within the cell[J]. Front Cell Dev Biol, 2020, 8:286-286.
[19]	赵丽娟, 李静, 吉淑敏. 糖尿病伴骨质疏松患者血清微小RNA-210胰岛素样生长因子结合蛋白-3的表达及临床价值[J]. 安徽医学, 2019, 40:1131-1134.
[20]	毛竹君, 柴可夫. 淫羊藿-仙茅药对调控miRNA-144保护高糖介导成骨细胞的作用机制[J]. 中华中医药杂志, 2019, 34:965-970.
[21]	王志刚, 刘菊. 利拉鲁肽对2型糖尿病骨质疏松大鼠miRNA-19a、miRNA-144及骨密度的影响[J]. 中国骨质疏松杂志, 2020, 26:1297-1300.
[22]	Zhang W, Wu Y, Shiozaki Y, et al. miRNA-133a-5p inhibits the expression of osteoblast differentiation-associated markers by targeting the 3′ UTR of RUNX2[J]. DNA Cell Biol, 2018, 37:199-209.
[23]	Zhang G, Li H, Zhao W, et al. miR-205 regulates bone turnover in elderly female patients with type 2 diabetes mellitus through targeted inhibition of Runx2[J]. Exp Ther Med, 2020, 20:1557-1565.
[24]	Wang X, Mi Y, He W, et al. Down-regulation of miR-340-5p promoted osteogenic differentiation through regulation of runt-related transcription factor-2 (RUNX2) in MC3T3-E1 cells[J]. Bioengineered, 2021, 12:1126-1137.
[25]	Qu B, He J, Zeng Z, et al. miR-155 inhibition alleviates suppression of osteoblastic differentiation by high glucose and free fatty acids in human bone marrow stromal cells by upregulating SIRT1[J]. Pflugers Arch, 2020, 472:473-480.
[26]	范德生, 甄蕾, 汪黎明. miRNA-31对糖尿病小鼠来源骨髓间充质干细胞体外成骨分化的影响[J]. 口腔颌面外科杂志, 2019, 29:137-141.
[27]	Zhen L, Jiang X, Chen Y, et al. miR-31 is involved in the high glucose-suppressed osteogenic differentiation of human periodontal ligament stem cells by targeting Satb2[J]. Am J Transl Res, 2017, 9:2384-2393.

MicroRNA在糖尿病性骨质疏松症中作用的研究进展

Research progress on the role of microRNA in diabetic osteoporosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李耀洋, 王书宇, 杨丹, 吴群励. 梁晓春教授治疗糖尿病肾脏病的用药经验[J]. 基础医学与临床, 2024, 44(9): 1335-1340.
[2]	彭晴怡, 许岭翎. 1型糖尿病诱发肌少症的研究进展[J]. 基础医学与临床, 2024, 44(8): 1189-1193.
[3]	赵俊丽, 朱君君, 詹秋楠, 刘苗. 骨髓间充质干细胞来源外泌体抑制高糖诱导的腹膜间皮细胞EMT[J]. 基础医学与临床, 2024, 44(8): 1149-1156.
[4]	王泽颖, 刘治, 邰玉, 杨忠彬, 苏燕. 转酮醇酶在糖尿病及其并发症发生和治疗中作用的研究进展[J]. 基础医学与临床, 2024, 44(7): 1023-1028.
[5]	齐梦亚, 李玉秀, 余洁, 张化冰, 许翎岭, 李伟, 平凡. 新确诊糖尿病患者增加运动与降低胰岛素抵抗和心血管危险因素相关[J]. 基础医学与临床, 2024, 44(7): 984-988.
[6]	宋佳, 赵峰, 张婷, 徐静, 孙静莉, 陈震宇. 人羊膜间充质干细胞对大鼠子宫瘢痕的修复作用[J]. 基础医学与临床, 2024, 44(7): 1002-1007.
[7]	龚金涛, 厉建伟, 李玉恒, 李堑, 赵春华. 骨髓间充质干细胞缓解模拟微重力对小鼠大脑皮质的不利影响[J]. 基础医学与临床, 2024, 44(6): 772-778.
[8]	刘潇, 王曌慧, 魏心怡, 周玥, 赵丽, 王玥, 李俊发. 糖尿病合并TREM2突变相关认知功能障碍的生物信息学分析[J]. 基础医学与临床, 2024, 44(5): 630-636.
[9]	何华美, 陆巍. miR-135a-5p通过调控CXCL12表达降低吗啡耐受[J]. 基础医学与临床, 2024, 44(5): 665-672.
[10]	高竞溪, 赵晓妍, 朱星雨, 孙昭, 韩钦, 赵春华. BM-MSCs延缓CD8⁺初始T细胞衰老[J]. 基础医学与临床, 2024, 44(5): 683-689.
[11]	王瑞, 柒铭铭, 杨微涛, 黄健, 肖锦艳, 李一春, 王永红, 刘燕萍. 综合营养管理对妊娠期糖尿病患者的血糖及妊娠结局的影响[J]. 基础医学与临床, 2024, 44(4): 434-439.
[12]	李娜, 李涛, 杨冬梨, 姚媛. 和厚朴酚抑制人脂肪间充质干细胞增殖[J]. 基础医学与临床, 2024, 44(4): 483-488.
[13]	秦小英, 刘慧, 韩冲芳, 贺建东. 改善昼夜节律紊乱减轻糖尿病大鼠心肌缺血/再灌注损伤[J]. 基础医学与临床, 2024, 44(2): 231-234.
[14]	张雅慧, 白琼. 低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(1): 114-118.
[15]	张伟才, 刘肆仁, 王尚农. 硫氢化钠增加高糖高脂条件下小鼠心房肌细胞系HL-1谷胱甘肽合成[J]. 基础医学与临床, 2024, 44(1): 69-76.